You may not have realized it, but making medicines is a dirty job.

A pair of new reports highlights the point: One finds troubling pollution emanating from plants in India that supply more than two dozen drug makers around the world, while the other underscores a failure by numerous antibiotic makers to disclosure discharges into the environment.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • May I observe that US-FDA can inspect for compliance with the cGMPs (Current Good Manufacturing Practices) which are US federal regulations. They get enough push back about ‘where is that in the regulations’ without adding environmental issues. Those are covered in the US (or nowadays, perhaps not) by the US EPA. I am not aware of the EPS working to ever do foreign inspections but I may be wrong – that does happen often.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy